Loading...

AVBP ARRIVENT BIOPHARMA INC Product Launches 8-K Filing

RRVN

VBP

ARRIVENT BIOPHARMA INC

(AVBP)

2025 8-K

Stock Offering Update

Financial Results Released

Presentation Announcement

Financial Results Report

Financial Results Announcement

Data Presentation

Product Expansion

Equity Offerings

Product Expansion

Financial Statements

Accounting Firm Change

Financial Results

License Agreement

Q3 Financial Results

Positive Trial Results

External Links:

On September 9, 2025, ArriVent BioPharma, Inc. announced the final analysis of firmonertinib monotherapy data from its global phase 1b study in EGFR PACC mutant non-small cell lung cancer, presented at the 2025 World Conference on Lung Cancer.

AI Assistant

ARRIVENT BIOPHARMA INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.